carboplatin,etoposide,atezolizumab,tiragolumab
roche
['skyscraper-02', 'tiragolumab']
#asco22 interim os of skyscraper-02 shows no difference in survival with addition of tiragolumab. median os of 13.6 months and control arm consistent with data seen from impower133. 
Director of Thoracic Oncology & Developmental Therapeutics @LombardiCancer, Associate Professor @Georgetown University #LCSM #HereWeGo #ITYSL He/Him